Sign Up
OverviewAPI
Sensorion, a clinical-stage biotechnology company, has announced the results of its mixed Annual General Meeting, with shareholders approving recommended resolutions. The company is focused on developing innovative therapies for hearing loss, collaborating with the Institut Pasteur for gene therapy and gene editing. Sensorion also has programs in small molecules for the treatment and prevention of hearing loss disorders.

Ask a question